Kazia Therapeutics Partners with QIMR Berghofer to Develop Innovative Cancer Immunotherapy NDL2

Kazia Therapeutics Partners with QIMR Berghofer to Advance Innovative Cancer Treatment

Kazia Therapeutics Limited announces a significant partnership with QIMR Berghofer, focusing on the development of a groundbreaking PD-L1 degrader program. This collaboration centers around the lead compound, NDL2, which is positioned as a first-in-class cancer immunotherapy. PD-L1 is a protein commonly utilized by cancer cells to evade detection by the immune system; it binds to the PD-1 receptor on T cells, effectively inactivating them. While traditional therapies like monoclonal antibodies aim to block this interaction, many patients face therapeutic resistance. NDL2 presents a novel solution by specifically targeting and degrading post-translationally modified forms of PD-L1, which are known to contribute to tumor progression and therapeutic resistance.

The mechanism of NDL2 involves a bicyclic peptide degrader that leverages the cell's protein disposal pathways to eliminate resistant forms of PD-L1 found across various cellular compartments. This innovative approach has the potential to restore immune activity and T-cell function within the tumor microenvironment. Preclinical studies demonstrate the effectiveness of NDL2 in reducing tumor growth, particularly in aggressive triple-negative breast cancer (TNBC) models. The compound shows promise both as a standalone treatment and in combination with existing anti-PD-1 therapies, while also maintaining a favorable safety profile devoid of toxicity.

The development strategy for NDL2 will initially target advanced breast cancer, with ongoing efforts to optimize its stability, potency, pharmacokinetics, and pharmacodynamics. Kazia Therapeutics collaborates closely with leading oncology peptide manufacturers to enhance the therapeutic properties of NDL2. This program not only aims to address the critical needs of primary non-responders and relapsed patients but also offers a beacon of hope for durable immune reactivation against tumors, potentially transforming the landscape of cancer immunotherapy.

In addition to the focus on NDL2, Kazia Therapeutics continues to explore other avenues within its pipeline, reflecting its commitment to advancing innovative cancer treatments. The collaboration with QIMR Berghofer highlights the company's strategic approach to harnessing cutting-edge research for patient benefit, underscoring its role in the evolving field of oncology.

As Kazia Therapeutics moves forward with this promising program, it positions itself at the forefront of cancer immunotherapy, addressing unmet medical needs and striving to improve patient outcomes in challenging cancer types.